scholarly journals Development of a method to determine the cost of breast cancer treatment with chemotherapy at Groote Schuur Hospital, Cape Town, South Africa

2020 ◽  
Vol 110 (4) ◽  
pp. 296
Author(s):  
N T Guzha ◽  
T Thebe ◽  
N Butler ◽  
P N Valodia
2021 ◽  
pp. 1316-1324
Author(s):  
Heloísa M. Resende ◽  
Leandro Ladislau ◽  
Ana Carolina F. Cardoso ◽  
Juliana Dinéia P. Brandão ◽  
Biazi R. Assis ◽  
...  

PURPOSE Breast cancer is the most common malignancy in Brazilian women, with 66,280 new cases in 2020 (with 20% overexpressing human epidermal growth factor receptor 2 [HER2]). The trastuzumab biosimilar was the first oncology biosimilar approved in Brazil for HER2-positive breast cancer treatment. This study aimed to assess the current level of knowledge of biosimilars, comfort of use, extrapolation indications, and switching of practices among oncologists in Brazil. METHODS A 24-question survey was developed using an online platform that sought information regarding responders' characteristics and use of biosimilars. The survey analyzed the basic knowledge of biosimilars, trastuzumab biosimilars, level of comfort with extrapolation, switching treatment regimens, and opinions concerning the cost of HER2-positive breast cancer therapy. Data were collected between July and September 2019 and included 144 oncologists from five Brazilian regions. RESULTS In total, 95% of respondents could identify the most appropriate definition of biosimilars and 96% felt comfortable prescribing trastuzumab biosimilars. Although 63% of respondents would use the biosimilar in all settings wherein the reference biologic was approved, 35% would use the biosimilar for cases involving metastatic disease. Although 82% of oncologists were in favor of switching from a reference biologic to a biosimilar, 18% would avoid switching regimens. The lack of studies detailing switching to other regimens and the correct timing to switch was the major concern. The cost of HER2 therapy was a significant concern for most oncologists. CONCLUSION Oncologists demonstrated a high level of knowledge of biosimilars and encouraging levels of prescriber use; however, extrapolation and switching treatment regimens are barriers to the effective use of biosimilars in cancer treatment. Efforts should be concentrated on strategies involving medical education programs on biosimilars.


2015 ◽  
Vol 33 (28_suppl) ◽  
pp. 74-74
Author(s):  
Donatus U. Ekwueme ◽  
Benjamin T. Allaire ◽  
Gery Guy ◽  
Sarah Arnold ◽  
Justin G Trogdon

74 Background: Breast cancer is the most common malignant tumor among women in the United States, accounting for about 30% of incident cancers. It is one of the most costly medical conditions to treat. Younger women aged 18-44 years account for 11% of new cases. These women tend to experience more aggressive types of breast cancer, requiring intensive and expensive treatment. In recent years, a few studies have examined the costs of breast cancer treatment in a Medicaid population at the state level. However, no study has estimated medical costs for breast cancer treatment at the national level for women aged 19-44 years enrolled in Medicaid. Methods: A sample of 5,542 younger women aged 19-44 years, fee-for-service Medicaid enrollees, and diagnosed with breast cancer in 2007 were compared with 4.3 million women aged 19-44 years, fee-for-service Medicaid enrollees, but without breast cancer. The study used linear and nonlinear regression methods to estimate treatment costs for younger women with breast cancer compared with those without breast cancer. Individual medical costs were estimated by race/ethnicity and by type of services. All medical treatment costs were adjusted to 2010 dollars. Results: The estimated annual direct medical costs for breast cancer treatment among younger women enrolled in Medicaid ranged from nearly $25,000 to $42,000 per woman. Non-Hispanic black women had the highest annual total medical costs, followed by Hispanic women, while non-Hispanic women of other race had the lowest. The cost estimates ranged from $14,600 to $18,800 for outpatient service, $4,600 to $5,700 for inpatient service, and $3,500 to $4,800 for prescription drugs. Conclusions: The cost estimates demonstrate the substantial medical costs associated with breast cancer treatment for younger Medicaid beneficiaries. As the Medicaid program continues to evolve, the treatment cost estimates could serve as important inputs in decision-making regarding planning for treatment of invasive breast cancer in this population.


Sign in / Sign up

Export Citation Format

Share Document